Baidu
map

The Lancet Oncology:前哨淋巴阳性的胸腺癌患者腋下放射治疗或手术治疗

2014-10-17 MedSci MedSci原创

对有阳性前哨淋巴结的乳腺癌患者来讲, 腋下淋巴结切除是目前常用的治疗手段。虽然腋下淋巴结切除具有极好的局域控制效果,但同时也有有害的副作用。研究人员在本次临床试验的目的就是为了评估是否腋下放射治疗能够作为一个具有较少副作用的局域控制方案。 研究方法: 外观无明显可触淋巴结病的原发性乳腺癌(T 1-2期)患者被选取进行该项具有随机性,多机构,开放性的非劣效性(non-inferiority)试验

对有阳性前哨淋巴结的乳腺癌患者来讲, 腋下淋巴结切除是目前常用的治疗手段。虽然腋下淋巴结切除具有极好的局域控制效果,但同时也有有害的副作用。研究人员在本次临床试验的目的就是为了评估是否腋下放射治疗能够作为一个具有较少副作用的局域控制方案。

研究方法:

外观无明显可触淋巴结病的原发性乳腺癌(T 1-2期)患者被选取进行该项具有随机性,多机构,开放性的非劣效性(non-inferiority)试验(EORTC 10981-22023 AMAROS)。具有阳性前哨淋巴结的乳腺癌患者以1:1的比例被电脑随机分派进行腋淋巴结切除或是腋下放射治疗。本次临床试验主要终点是检测该疗法的5年腋下复发的非劣效性,即,相对腋下淋巴结切除组预期为2%的复发,腋下放射组不高于4%。所有分析均严格按照试验方案进行。

研究结果:

试验自2001年2月19日起至2010年4月29日止,历时9年多。根据随机原则,来自9个欧洲国家34个机构的4806名受试患者进行了这项试验。2402名患者被随机指定接受腋下淋巴切除手术,而2404名患者接受腋下放射治疗。在1425名阳性前哨淋巴结患者中,744人被随机指定进行腋下淋巴切除手术,而681名患者接受腋下放射治疗。这些患者构成了本次试验的ITT集(intention-to-treat)群体。阳性前哨淋巴结患者的随访中位数为6.1年(IQR 4.1-8.0)。在腋下淋巴切除组中,220名患者表现有阳性淋巴结,这占到了全部672名受试患者的33%。 腋下切除组和放射组的腋下复发率分别为0.5%(4/744)和1%(7/681)。 腋下切除组和放射组的5年腋下复发率为0.43% (95% CI 0.00-0.92) 和 1.19% (0.31-2.08)。 由于受到样品量的限制,原来设定的非劣性检测功效较低。单侧检测的可信区间(CI)值为95%, 该低效非劣性检测危害比为0.00-5.27,非劣效性界值(non-inferiority margin)为2。 在第1年、第2年及第5年, 腋下切除组中同侧手臂淋巴水肿较腋下放射组更为显著。

结论:

腋下淋巴切除和腋下放射治疗为阳性前哨淋巴结原发性胸腺癌及非可触及淋巴结病患者提供了一个效果极佳的腋下控制治疗方案。而且腋下放射疗法则具有更好的治疗效果。

本文是MedSci原创编译整理,欢迎转载!转载请注明来源并附原文链接。谢谢!

原始出处

Mila Donker, Geertjan van Tienhoven, Marieke E Straver, Philip Meijnen, Prof Cornelis J H van de Velde, Prof Robert E Mansel, Prof Luigi Cataliotti, A Helen Westenberg, Prof Jean H G Klinkenbijl, Lorenzo Orzalesi, Willem H Bouma, Huub C J van der Mijle, Grard A P Nieuwenhuijzen MD k, Sanne C Veltkamp MD l, Leen Slaets PhD m, Nicole J Duez MSc m, Peter W de Graaf MD n, Thijs van Dalen MD o, Andreas Marinelli MD p, Herman Rijna MD q, Prof Marko Snoj MD r, Prof Nigel J Bundred MD s, Jos W S Merkus MD t, Prof Yazid Belkacemi MD u, Prof Patrick Petignat, Dominic A X Schinagl MD w, Corneel Coens MSc x, Carlo G M Messina, Jan Bogaerts, Prof Emiel J T Rutgers.Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial.The Lancet Oncology. 16 October 2014
 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1674338, encodeId=4ec116e4338b1, content=<a href='/topic/show?id=e8aa13359b1' target=_blank style='color:#2F92EE;'>#Oncology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13359, encryptionId=e8aa13359b1, topicName=Oncology)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb7226973259, createdName=circumcision, createdTime=Sun Nov 09 13:40:00 CST 2014, time=2014-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1663462, encodeId=a1bd16634624c, content=<a href='/topic/show?id=451a8418304' target=_blank style='color:#2F92EE;'>#胸腺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84183, encryptionId=451a8418304, topicName=胸腺)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fcbd25619530, createdName=1508842480_96220445, createdTime=Fri Oct 31 15:40:00 CST 2014, time=2014-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1827891, encodeId=8e67182e8910f, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Fri Feb 27 13:40:00 CST 2015, time=2015-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864547, encodeId=3dab186454e48, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Thu Nov 13 16:40:00 CST 2014, time=2014-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2078098, encodeId=704c20e809808, content=<a href='/topic/show?id=612e8419336' target=_blank style='color:#2F92EE;'>#胸腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84193, encryptionId=612e8419336, topicName=胸腺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce5632, createdName=jianjun66, createdTime=Sun Feb 08 11:40:00 CST 2015, time=2015-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=12302, encodeId=2e3012302d6, content=是乳腺不是胸腺, beContent=null, objectType=article, channel=null, level=null, likeNumber=146, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Wed Oct 22 04:10:00 CST 2014, time=2014-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1290554, encodeId=eab4129055408, content=<a href='/topic/show?id=e86454454ea' target=_blank style='color:#2F92EE;'>#手术治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54454, encryptionId=e86454454ea, topicName=手术治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=920c231, createdName=lixiaol, createdTime=Sun Oct 19 06:40:00 CST 2014, time=2014-10-19, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1674338, encodeId=4ec116e4338b1, content=<a href='/topic/show?id=e8aa13359b1' target=_blank style='color:#2F92EE;'>#Oncology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13359, encryptionId=e8aa13359b1, topicName=Oncology)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb7226973259, createdName=circumcision, createdTime=Sun Nov 09 13:40:00 CST 2014, time=2014-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1663462, encodeId=a1bd16634624c, content=<a href='/topic/show?id=451a8418304' target=_blank style='color:#2F92EE;'>#胸腺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84183, encryptionId=451a8418304, topicName=胸腺)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fcbd25619530, createdName=1508842480_96220445, createdTime=Fri Oct 31 15:40:00 CST 2014, time=2014-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1827891, encodeId=8e67182e8910f, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Fri Feb 27 13:40:00 CST 2015, time=2015-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864547, encodeId=3dab186454e48, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Thu Nov 13 16:40:00 CST 2014, time=2014-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2078098, encodeId=704c20e809808, content=<a href='/topic/show?id=612e8419336' target=_blank style='color:#2F92EE;'>#胸腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84193, encryptionId=612e8419336, topicName=胸腺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce5632, createdName=jianjun66, createdTime=Sun Feb 08 11:40:00 CST 2015, time=2015-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=12302, encodeId=2e3012302d6, content=是乳腺不是胸腺, beContent=null, objectType=article, channel=null, level=null, likeNumber=146, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Wed Oct 22 04:10:00 CST 2014, time=2014-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1290554, encodeId=eab4129055408, content=<a href='/topic/show?id=e86454454ea' target=_blank style='color:#2F92EE;'>#手术治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54454, encryptionId=e86454454ea, topicName=手术治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=920c231, createdName=lixiaol, createdTime=Sun Oct 19 06:40:00 CST 2014, time=2014-10-19, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1674338, encodeId=4ec116e4338b1, content=<a href='/topic/show?id=e8aa13359b1' target=_blank style='color:#2F92EE;'>#Oncology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13359, encryptionId=e8aa13359b1, topicName=Oncology)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb7226973259, createdName=circumcision, createdTime=Sun Nov 09 13:40:00 CST 2014, time=2014-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1663462, encodeId=a1bd16634624c, content=<a href='/topic/show?id=451a8418304' target=_blank style='color:#2F92EE;'>#胸腺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84183, encryptionId=451a8418304, topicName=胸腺)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fcbd25619530, createdName=1508842480_96220445, createdTime=Fri Oct 31 15:40:00 CST 2014, time=2014-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1827891, encodeId=8e67182e8910f, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Fri Feb 27 13:40:00 CST 2015, time=2015-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864547, encodeId=3dab186454e48, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Thu Nov 13 16:40:00 CST 2014, time=2014-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2078098, encodeId=704c20e809808, content=<a href='/topic/show?id=612e8419336' target=_blank style='color:#2F92EE;'>#胸腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84193, encryptionId=612e8419336, topicName=胸腺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce5632, createdName=jianjun66, createdTime=Sun Feb 08 11:40:00 CST 2015, time=2015-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=12302, encodeId=2e3012302d6, content=是乳腺不是胸腺, beContent=null, objectType=article, channel=null, level=null, likeNumber=146, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Wed Oct 22 04:10:00 CST 2014, time=2014-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1290554, encodeId=eab4129055408, content=<a href='/topic/show?id=e86454454ea' target=_blank style='color:#2F92EE;'>#手术治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54454, encryptionId=e86454454ea, topicName=手术治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=920c231, createdName=lixiaol, createdTime=Sun Oct 19 06:40:00 CST 2014, time=2014-10-19, status=1, ipAttribution=)]
    2015-02-27 howi
  4. [GetPortalCommentsPageByObjectIdResponse(id=1674338, encodeId=4ec116e4338b1, content=<a href='/topic/show?id=e8aa13359b1' target=_blank style='color:#2F92EE;'>#Oncology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13359, encryptionId=e8aa13359b1, topicName=Oncology)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb7226973259, createdName=circumcision, createdTime=Sun Nov 09 13:40:00 CST 2014, time=2014-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1663462, encodeId=a1bd16634624c, content=<a href='/topic/show?id=451a8418304' target=_blank style='color:#2F92EE;'>#胸腺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84183, encryptionId=451a8418304, topicName=胸腺)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fcbd25619530, createdName=1508842480_96220445, createdTime=Fri Oct 31 15:40:00 CST 2014, time=2014-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1827891, encodeId=8e67182e8910f, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Fri Feb 27 13:40:00 CST 2015, time=2015-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864547, encodeId=3dab186454e48, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Thu Nov 13 16:40:00 CST 2014, time=2014-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2078098, encodeId=704c20e809808, content=<a href='/topic/show?id=612e8419336' target=_blank style='color:#2F92EE;'>#胸腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84193, encryptionId=612e8419336, topicName=胸腺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce5632, createdName=jianjun66, createdTime=Sun Feb 08 11:40:00 CST 2015, time=2015-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=12302, encodeId=2e3012302d6, content=是乳腺不是胸腺, beContent=null, objectType=article, channel=null, level=null, likeNumber=146, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Wed Oct 22 04:10:00 CST 2014, time=2014-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1290554, encodeId=eab4129055408, content=<a href='/topic/show?id=e86454454ea' target=_blank style='color:#2F92EE;'>#手术治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54454, encryptionId=e86454454ea, topicName=手术治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=920c231, createdName=lixiaol, createdTime=Sun Oct 19 06:40:00 CST 2014, time=2014-10-19, status=1, ipAttribution=)]
    2014-11-13 minlingfeng
  5. [GetPortalCommentsPageByObjectIdResponse(id=1674338, encodeId=4ec116e4338b1, content=<a href='/topic/show?id=e8aa13359b1' target=_blank style='color:#2F92EE;'>#Oncology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13359, encryptionId=e8aa13359b1, topicName=Oncology)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb7226973259, createdName=circumcision, createdTime=Sun Nov 09 13:40:00 CST 2014, time=2014-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1663462, encodeId=a1bd16634624c, content=<a href='/topic/show?id=451a8418304' target=_blank style='color:#2F92EE;'>#胸腺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84183, encryptionId=451a8418304, topicName=胸腺)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fcbd25619530, createdName=1508842480_96220445, createdTime=Fri Oct 31 15:40:00 CST 2014, time=2014-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1827891, encodeId=8e67182e8910f, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Fri Feb 27 13:40:00 CST 2015, time=2015-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864547, encodeId=3dab186454e48, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Thu Nov 13 16:40:00 CST 2014, time=2014-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2078098, encodeId=704c20e809808, content=<a href='/topic/show?id=612e8419336' target=_blank style='color:#2F92EE;'>#胸腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84193, encryptionId=612e8419336, topicName=胸腺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce5632, createdName=jianjun66, createdTime=Sun Feb 08 11:40:00 CST 2015, time=2015-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=12302, encodeId=2e3012302d6, content=是乳腺不是胸腺, beContent=null, objectType=article, channel=null, level=null, likeNumber=146, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Wed Oct 22 04:10:00 CST 2014, time=2014-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1290554, encodeId=eab4129055408, content=<a href='/topic/show?id=e86454454ea' target=_blank style='color:#2F92EE;'>#手术治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54454, encryptionId=e86454454ea, topicName=手术治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=920c231, createdName=lixiaol, createdTime=Sun Oct 19 06:40:00 CST 2014, time=2014-10-19, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1674338, encodeId=4ec116e4338b1, content=<a href='/topic/show?id=e8aa13359b1' target=_blank style='color:#2F92EE;'>#Oncology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13359, encryptionId=e8aa13359b1, topicName=Oncology)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb7226973259, createdName=circumcision, createdTime=Sun Nov 09 13:40:00 CST 2014, time=2014-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1663462, encodeId=a1bd16634624c, content=<a href='/topic/show?id=451a8418304' target=_blank style='color:#2F92EE;'>#胸腺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84183, encryptionId=451a8418304, topicName=胸腺)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fcbd25619530, createdName=1508842480_96220445, createdTime=Fri Oct 31 15:40:00 CST 2014, time=2014-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1827891, encodeId=8e67182e8910f, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Fri Feb 27 13:40:00 CST 2015, time=2015-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864547, encodeId=3dab186454e48, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Thu Nov 13 16:40:00 CST 2014, time=2014-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2078098, encodeId=704c20e809808, content=<a href='/topic/show?id=612e8419336' target=_blank style='color:#2F92EE;'>#胸腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84193, encryptionId=612e8419336, topicName=胸腺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce5632, createdName=jianjun66, createdTime=Sun Feb 08 11:40:00 CST 2015, time=2015-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=12302, encodeId=2e3012302d6, content=是乳腺不是胸腺, beContent=null, objectType=article, channel=null, level=null, likeNumber=146, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Wed Oct 22 04:10:00 CST 2014, time=2014-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1290554, encodeId=eab4129055408, content=<a href='/topic/show?id=e86454454ea' target=_blank style='color:#2F92EE;'>#手术治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54454, encryptionId=e86454454ea, topicName=手术治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=920c231, createdName=lixiaol, createdTime=Sun Oct 19 06:40:00 CST 2014, time=2014-10-19, status=1, ipAttribution=)]
    2014-10-22 匿名用户

    是乳腺不是胸腺

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1674338, encodeId=4ec116e4338b1, content=<a href='/topic/show?id=e8aa13359b1' target=_blank style='color:#2F92EE;'>#Oncology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13359, encryptionId=e8aa13359b1, topicName=Oncology)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb7226973259, createdName=circumcision, createdTime=Sun Nov 09 13:40:00 CST 2014, time=2014-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1663462, encodeId=a1bd16634624c, content=<a href='/topic/show?id=451a8418304' target=_blank style='color:#2F92EE;'>#胸腺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84183, encryptionId=451a8418304, topicName=胸腺)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fcbd25619530, createdName=1508842480_96220445, createdTime=Fri Oct 31 15:40:00 CST 2014, time=2014-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1827891, encodeId=8e67182e8910f, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Fri Feb 27 13:40:00 CST 2015, time=2015-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864547, encodeId=3dab186454e48, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Thu Nov 13 16:40:00 CST 2014, time=2014-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2078098, encodeId=704c20e809808, content=<a href='/topic/show?id=612e8419336' target=_blank style='color:#2F92EE;'>#胸腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84193, encryptionId=612e8419336, topicName=胸腺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce5632, createdName=jianjun66, createdTime=Sun Feb 08 11:40:00 CST 2015, time=2015-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=12302, encodeId=2e3012302d6, content=是乳腺不是胸腺, beContent=null, objectType=article, channel=null, level=null, likeNumber=146, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Wed Oct 22 04:10:00 CST 2014, time=2014-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1290554, encodeId=eab4129055408, content=<a href='/topic/show?id=e86454454ea' target=_blank style='color:#2F92EE;'>#手术治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54454, encryptionId=e86454454ea, topicName=手术治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=920c231, createdName=lixiaol, createdTime=Sun Oct 19 06:40:00 CST 2014, time=2014-10-19, status=1, ipAttribution=)]

相关资讯

Ann Thorac Surg:胸腺癌术中淋巴结清扫可使患者获益

对于肿瘤患者而言,淋巴结清扫在其手术中起着重要的作用。然而淋巴结清扫在胸腺癌中的作用方面数据仍比较缺乏。针对这种情况,来自韩国首尔国立大学医院的首尔国立大学医院In Kyu Park教授等人进行了一项研究,研究结果在线发表于2013年7月24日的《胸外科年鉴》(Annals of Surgical)杂志上。作者发现广泛的淋巴节清扫,10个以上淋巴结,才能准确地预测患者的预后。同时,前纵隔及右气管旁

Baidu
map
Baidu
map
Baidu
map